open access
Is there a future for cell-free fetal dna tests in screening for preeclampsia?
Affiliations- First Department of Obstetrics and Gynaecology, Medical University of Warsaw, Poland
open access
Abstract
CffDNA screening is a powerful diagnostic tool in the prenatal diagnosis algorithm for chromosomal abnormalities. With detailed ultrasound examination as the mainstay of first-trimester risk assessment, cffDNA has been shown to be superior to first-trimester combined screening (FTCS) in false-positive rates for trisomy 21 detection. In light of the growing interest in cffDNA testing and the possibility of it replacing first-trimester biochemistry, we decided to investigate the usefulness of cffDNA tests in early-pregnancy risk assessment for preeclampsia (PE). The aim of this review paper was to evaluate clinical application of first-trimester cfDNA in predicting PE, as well as to investigate its possible use in first-trimester PE screening enhancement, also in cases where biochemistry is not performed.
Abstract
CffDNA screening is a powerful diagnostic tool in the prenatal diagnosis algorithm for chromosomal abnormalities. With detailed ultrasound examination as the mainstay of first-trimester risk assessment, cffDNA has been shown to be superior to first-trimester combined screening (FTCS) in false-positive rates for trisomy 21 detection. In light of the growing interest in cffDNA testing and the possibility of it replacing first-trimester biochemistry, we decided to investigate the usefulness of cffDNA tests in early-pregnancy risk assessment for preeclampsia (PE). The aim of this review paper was to evaluate clinical application of first-trimester cfDNA in predicting PE, as well as to investigate its possible use in first-trimester PE screening enhancement, also in cases where biochemistry is not performed.
Keywords
cell-free fetal DNA; cffDNA; cell-free DNA; cfDNA; preeclampsia; PE; first-trimester screening; first-trimester combined screening
About this articleTitle
Is there a future for cell-free fetal dna tests in screening for preeclampsia?
Journal
Issue
Article type
Review paper
Pages
55-60
Published online
2019-01-31
Page views
2676
Article views/downloads
2178
DOI
Pubmed
Bibliographic record
Ginekol Pol 2019;90(1):55-60.
Keywords
cell-free fetal DNA
cffDNA
cell-free DNA
cfDNA
preeclampsia
PE
first-trimester screening
first-trimester combined screening
Authors
Urszula Sarzynska-Nowacka
Przemyslaw Kosinski
Miroslaw Wielgos
References (35)- Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997; 350(9076): 485–487.
- Lo YM, Lau TK, Zhang J, et al. Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21. Clin Chem. 1999; 45(10): 1747–1751.
- Gil MM, Quezada MS, Revello R, et al. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015; 45(3): 249–266.
- Kagan KO, Sroka F, Sonek J, et al. First-trimester risk assessment based on ultrasound and cell-free DNA vs combined screening: a randomized controlled trial. Ultrasound Obstet Gynecol. 2018; 51(4): 437–444.
- Wataganara T, Metzenbauer M, Peter I, et al. Placental volume, as measured by 3-dimensional sonography and levels of maternal plasma cell-free fetal DNA. Am J Obstet Gynecol. 2005; 193(2): 496–500.
- O'Gorman N, Wright D, Rolnik DL, et al. Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE). BMJ Open. 2016; 6(6): e011801.
- Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017; 216(2): 110–120.e6.
- Rolnik DL, Wright D, Poon LCY, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017; 50(4): 492–495.
- Kosinski P, Sarzynska-Nowacka U, Fiolna M, et al. The practical use of acetylsalicylic acid in the era of the ASPRE trial. Update and literature review. Ginekol Pol. 2018; 89(2): 107–111.
- Alberry MS, Maddocks DG, Hadi MA, et al. Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. Am J Obstet Gynecol. 2009; 200(1): 98.e1–98.e6.
- Contro E, Bernabini D, Farina A. Cell-Free Fetal DNA for the Prediction of Pre-Eclampsia at the First and Second Trimesters: A Systematic Review and Meta-Analysis. Mol Diagn Ther. 2017; 21(2): 125–135.
- Lau TW, Leung TN, Chan LYS, et al. Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clin Chem. 2002; 48(12): 2141–2146.
- Chan KC, Ding C, Gerovassili A, et al. Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem. 2006; 52(12): 2211–2218.
- Salvianti F, Inversetti A, Smid M, et al. Prospective evaluation of RASSF1A cell-free DNA as a biomarker of pre-eclampsia. Placenta. 2015; 36(9): 996–1001.
- Jani J, Rego de Sousa MJ, Benachi A. Cell-free DNA testing: how to choose which laboratory to use? Ultrasound Obstet Gynecol. 2015; 46(5): 515–517.
- Chiu RWK, Lo YM. Noninvasive prenatal diagnosis empowered by high-throughput sequencing. Prenat Diagn. 2012; 32(4): 401–406.
- Ashoor G, Syngelaki A, Poon LCY, et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013; 41(1): 26–32.
- Revello R, Sarno L, Ispas A, et al. Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result. Ultrasound Obstet Gynecol. 2016; 47(6): 698–704.
- Rolnik DL, da Silva Costa F, Lee TJ, et al. Association between fetal fraction on cell-free DNA testing and first-trimester markers for pre-eclampsia. Ultrasound Obstet Gynecol. 2018; 52(6): 722–727.
- Wang E, Batey A, Struble C, et al. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn. 2013; 33(7): 662–666.
- Wright D, Wright A, Nicolaides KH. A unified approach to risk assessment for fetal aneuploidies. Ultrasound Obstet Gynecol. 2015; 45(1): 48–54.
- Gil MM, Accurti V, Santacruz B, et al. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2017; 50(3): 302–314.
- Norton M, Musci T, Wapner R. 358: Relationship between 1st trimester fetal fraction of cell-free DNA from maternal plasma and preeclampsia in a large general pregnancy population. American Journal of Obstetrics and Gynecology. 2015; 212(1): S188.
- Sifakis S, Zaravinos A, Maiz N, et al. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol. 2009; 201(5): 472.e1–472.e7.
- Papantoniou N, Bagiokos V, Agiannitopoulos K, et al. RASSF1A in maternal plasma as a molecular marker of preeclampsia. Prenat Diagn. 2013; 33(7): 682–687.
- Room TB, Lauderdale F, Goldberg IJ. HHS Public Access. 2015; 12(2): 130–40.
- Poon LCY, Musci T, Song K, et al. Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes. Fetal Diagn Ther. 2013; 33(4): 215–223.
- Rolnik DL, O'Gorman N, Fiolna M, et al. Maternal plasma cell-free DNA in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2015; 45(1): 106–111.
- Thurik FF, Lamain-de Ruiter M, Javadi A, et al. Absolute first trimester cell-free DNA levels and their associations with adverse pregnancy outcomes. Prenat Diagn. 2016; 36(12): 1104–1111.
- Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies. JAMA. 2015; 314(2): 162–169.
- Kulasingam V, Diamandis EP, Cohen PA, et al. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening. BMC Med. 2016; 14(1): 126.
- Bennett J, Chitty L, Lewis C. Non-invasive Prenatal Diagnosis for BRCA Mutations - a Qualitative Pilot Study of Health Professionals' Views. J Genet Couns. 2016; 25(1): 198–207.
- Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med. 2011; 13(11): 913–920.
- Gratacós E, Nicolaides K. Clinical perspective of cell-free DNA testing for fetal aneuploidies. Fetal Diagn Ther. 2014; 35(3): 151–155.
- Kim MJ, Kim SY, Park SY, et al. Association of fetal-derived hypermethylated RASSF1A concentration in placenta-mediated pregnancy complications. Placenta. 2013; 34(1): 57–61.
